Home > Healthcare > Medical Devices > Diagnostic Devices > Radiotheranostics Market
Radiotheranostics Market size was valued at around USD 2 billion in 2023 and is anticipated to register a CAGR of over 14.6% between 2024 and 2032. Radiotheranostics is a medical approach that combines the principles of radiotherapy and diagnostics utilizing radiopharmaceuticals for both therapeutic treatment and diagnostic imaging.
This integrated approach allows for personalized and targeted management of various diseases particularly cancer and certain other conditions. Radiotheranostics involves the use of radiopharmaceuticals labeled with radioactive isotopes emitting radiation suitable for imaging and therapy. The increasing prevalence of cancer is a significant driver for the market.
Report Attribute | Details |
---|---|
Base Year: | 2023 |
Radiotheranostics Market Size in 2023: | USD 2 Billion |
Forecast Period: | 2024 - 2032 |
Forecast Period 2024 - 2032 CAGR: | 14.6% |
2032 Value Projection: | USD 6.6 Billion |
Historical Data for: | 2021 – 2023 |
No. of Pages: | 190 |
Tables, Charts & Figures: | 233 |
Segments covered: | Radioisotope, Approach, Application, and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
For instance, according to World Health Organization (WHO) in 2020, reported that cancer emerged as a prominent contributor to global mortality, claiming approximately 10 million lives globally. Thus, the demand for radiotheranostics offers a vital dual approach of precise diagnosis and targeted therapy to improved patient outcomes. Furthermore, market growth is attributed to multiple factors, including the growing use of radiotheranostics in cancer diagnostics, which estimated to reach USD 324 billion by 2032, and management and increasing trend of nuclear medicine.